These findings suggested that enhanced expression of FTO/SP1/AURKB signaling in GC might also in-deeply control its malignant progression through regulation of tumor immune microenvironment, which could be very detrimental to the treatment and prognosis of patients. The gene discussed is FTO; the disease is gastric cancer.